Tag Archives: USPTO

Senate Committee Releases Outline for Section 101 Reform

Posted on April 18, 2019 by Warren Woessner

On April 18th, the Senate Judiciary Subcommittee on Intellectual Property released a “Draft Outline of Section 101 Reform” that is intended to provide the basis of legislative amendments to the requirements for patent reform. Apart from the proposal to effectively … Continue reading →

Posted in Patent Eligible Subject Matter, Patent Reform Legislation | Tagged , , , , , , | Leave a comment

Cleveland Clinic II – Why Can’t a Diagnostic Conclusion be a Practical Application of a Natural Law?

Posted on April 4, 2019 by Warren Woessner

Because the Federal Circuit says it can’t, that’s why!  In Cleveland Clinic Foundation v. True Health Diagnostics LLC, 859 F.3d 1352 (Fed. Cir. 2017), the panel held patent-ineligible claims to a method of assessing a test subject’s risk of having … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

Ex parte Ren-Hie Xu – Are Cultured Mammalian Cells Natural Products?

Posted on March 27, 2019 by Warren Woessner

The Examiner in Appeal no. 2017-003416 (Mar. 1, 2019) had rejected this claim as directed to a natural product: “18. An in vitro culture comprising a substantially pure, replenishable population of synchronous primate trophoblast cells, wherein the synchronous primate trophoblast … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment

Hikma and West-Ward v. Vanda – Are Methods of Medical Treatment Patent-Eligible?

Posted on March 5, 2019 by Warren Woessner

Hikma Pharms. and West-Ward Pharms petition for cert. to reverse the Fed. Cir.’s decision in Vanda v. West-Ward that methods of medical treatment are patentable. The Supreme Court’s now-infamous Mayo decision, invalidated claims to a method for determining the optimal … Continue reading →

Posted in 2017 Patent Review | Tagged , , , , , | Leave a comment